AI-powered evaluation using the Model Context Optimization BS Detection Framework, based solely on publicly available website content.
Based on 784 businesses audited.
Genentech has 19.7 points less BS than the average for Medical Devices, Pharma & Biotech.
Medical Devices, Pharma & Biotech BS: Genentech (avastin.com)
A rare example of high-integrity communication forced by regulation but executed with precision. While the site is highly repetitive, it replaces traditional marketing BS with dense clinical data and surprisingly transparent limitations of the therapy. It is a ‘Substance-First’ site where the legal disclosures provide more forensic evidence than the promotional headings.
To further reduce the BS score, Genentech should reduce the verbatim duplication of content between the homepage and the mCRC sub-page to minimize concept repetition penalties. Adding direct outbound links to ClinicalTrials.gov identifiers for the referenced studies within the body text would improve the proof path score. The trust_theatre_flag could be neutralized by integrating a more robust, verified professional review system for HCPs. Finally, adding ‘Person’ schema for the lead medical directors or clinical leads would close the minor authority gap for individual expertise.
Information density is exceptionally high for a commercial site, as it is heavily weighted toward clinical and regulatory data. The site provides specific figures such as co-pay assistance up to $25,000 and clinical observation rates like the 0.4% incidence of severe infusion-related reactions. Fluff is minimal, though the use of the trademarked metaphor tumor-starving therapy appears across multiple headings, serving as a branded hook rather than a technical descriptor. Substance is found in the detailed administration cycles and specific exclusion criteria for surgery and pregnancy.
Most sites "have schema," but AI still cannot understand what their pages represent. Run a Structured Data AI Audit to see what entity types your pages actually resolve into.
There is zero detectable semantic drift between the homepage and the sub-pages. The homepage establishes the primary signal of metastatic colorectal cancer (mCRC) treatment and financial support, which the sub-pages deliver with identical language and structure. The recurrent glioblastoma (rGBM) page maintains the same messaging framework, ensuring that the brand promise of ‘blocking VEGF’ is the central theme across all therapeutic areas without any identity shifts or contradictory service levels.
Our Authority as a Service model transforms raw diagnostic data into high stakes results. Start your Clinical Strategic Diagnosis for 1 Euro to secure the strategic fixes required for growth.
The site carries a trust_theatre_flag because it presents highly controlled medical claims with limited external peer-review links in the immediate text, although it references FDA and clinical studies throughout. The review_count of 1 without a corresponding verified proof_link suggests a placeholder or a very limited feedback loop. However, the substance of the ‘Important Safety Information’ blocks acts as a legal counterweight to traditional marketing fluff, providing a level of transparency (e.g., admitting that in certain studies, tumors did not shrink) rarely seen in other industries.
The ratio of evidence to fluff is high. Evidence points include specific FDA reporting phone numbers (1-800-FDA-1088), the exact dosage of the co-pay card, and specific timeline contraindications (28 days before or after surgery). Vague assertions are virtually non-existent; every claim about what the drug ‘may’ do is immediately followed by a list of what it specifically ‘can’ do in terms of side effects, providing a balanced and proof-heavy narrative.
To evaluate URL identity stability and multilingual coherence, review the Yoast Identity Stability audit. View the Yoast Identity Stability Audit for a practical example of canonical alignment and language layer integrity.
The fingerprint is influenced by heavy pharmaceutical boilerplate, specifically the ‘Important Safety Information’ and ‘Indication’ sections which are standard for Genentech products. Industry cliches like ‘breakthrough innovation’ are avoided in favor of specific jargon such as ‘vascular endothelial growth factor’ and ‘intravenous (IV) infusion.’ The most common template fingerprint is the repeated use of ‘Patient Resources’ and ‘Out-of-Pocket Support’ blocks across all pages, which are generic in structure but contain highly specific financial limits and program names.
Authority is primarily institutional rather than individual, which is standard for pharmaceutical manufacturing. The schema_json correctly identifies the parent Organization as Genentech with its South San Francisco headquarters and contact points. There are no gaps in regulatory authority, as the site provides explicit instructions for reporting side effects to the FDA and Genentech, establishing a high degree of technical credibility. The lack of Person schema for individual researchers is not a penalty in this context as the brand entity carries the liability and authority.
Unlike most B2B sites, the performance claims here are tempered by clinical reality. For instance, on the ‘How Avastin Works’ page, the site explicitly states that in a study of mCRC patients, tumors did not shrink, even while explaining the mechanism of action. This negative disclosure demonstrates a high level of substance and reduces the distance between marketing signal and forensic reality. Most claims are tied to specific clinical outcomes or financial eligibility criteria.
Medical Devices, Pharma & Biotech BS: Genentech (avastin.com)
The website perfectly aligns with the Pharma and Biotech industry classification. Its content is strictly focused on therapeutic indications, mechanism of action (VEGF inhibition), and regulatory-mandated safety disclosures for the drug Avastin.
Every retrieval error rooted in "wrong page surfaced" begins with one failure: unstable URL identity. Read the URL & Canonical Technical Guide to learn how consistent paths and canonical alignment preserve semantic cohesion.
“The score of 21 is driven primarily by industry clichés and repetition. The Information Density and Semantic Coherence pillars are extremely strong, showing almost no fluff or drift. The score remains above 10 only because of the heavy use of template language and the high number of content repetitions across the four analyzed pages.”
Analysis Disclosure & Source Attribution
Snapshot Date: May 29, 2026
Purpose: This data is presented under “Fair Use” / “Educational Exception” for the purpose of forensic semantic analysis, allowing users to see how machine logic interprets digital signals.
Machine Perception Notice: This evaluation is generated by machine-read logic (MRL). The AI interprets the “Digital Ghost” of a website (code, metadata, and semantic structures), which may differ from what a human sees at the same moment. This is an automated technical diagnostic and not a statement of fact or human opinion regarding the real-world integrity or legitimacy of the business. Any missing or inaccessible elements in the snapshot are treated as machine-read signals, reflecting AI rendering limitations rather than intentional omission.
Notice to the Evaluated Business: This analysis is part of a non-adversarial audit. The results are intended as professional feedback to help improve machine-readability and authority signals. Any company can use these insights for free. When content is updated, a fresh audit can be requested at any time to reflect the current state.
To All Users: You are encouraged to visit the live site at Genentech to view the most current version of their content and see directly what the company offers.